Pediatric Neuroblastoma Treatment Market is expected to reach US$ 3.88 Bn. at a CAGR of 10.2% during the forecast period 2029. Neuroblastoma (NB) is common cancer, which is arise in childhood and infancy. Development of Neuroblastoma is starts in primitive nerve cells. It rarely occurs later age around 10 years. Neuroblastoma is occasionally triggered by a gene mutation transferred from parent to child. It can develop in nerves near the backbone and also in the spinal cord, neck, chest, or abdomen. Several common symptoms of the neuroblastoma are bulging eyes, anemia, weakness, firm mass in abdomen, weight, crankiness, fever, enlarged stomach, bone pain, dark circles around the eyes, and high blood pressure.To know about the Research Methodology :- Request Free Sample Report The scope of the report includes a detailed study of global and regional markets for Pediatric Neuroblastoma Treatment with the reasons given for variants in the growth of the industry in certain regions.The report study has analyzed revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers and market disrupters in the report and same is reflected in our analysis. A variety of medications or drugs has been accepted to treat the metastatic neuroblastoma, like immunotherapy and chemotherapy. The neuroblastoma treatment market is primarily driven by the increasing occurrences of cancer in globe. Developing healthcare expenditures is additional key aspect to drive the neuroblastoma treatment market. Nevertheless, certain issues like high cost treatment is anticipated to hamper growth of neuroblastoma treatment market. U.S. demonstrations incidence of approximately 650 cases every year. Therefore, increase in R&D expenditure, rise in occurrence of neuroblastoma between children, and increase in awareness about existing treatments are the factors expected to expand the market throughout the forecast period. Furthermore, innovation in technology and development in health care infrastructure are anticipated to drive the pediatric neuroblastoma treatment market throughout the forecast period. The report on Pediatric Neuroblastoma Treatment market covers segments such as Therapy Type, Distribution Channel and Region. The Therapy Type segment includes Immunotherapy, Chemotherapy, and Others. Among the Therapy Type, Immunotherapy is accounted for the largest xx% market share in the market. The Distribution Channel segment is further sub-segmented into Hospital Pharmacies, Retail Pharmacies & Drug Stores, and Others. Among the Distribution Channel, Hospital Pharmacies is accounted for the largest xx% market share in the Pediatric Neuroblastoma Treatment market. Based on regional segment, the Pediatric Neuroblastoma Treatment market is sub-segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America was dominated the market in 2018. As per American Cancer Society’s Cancer Statistics, approximately 800 new cases of neuroblastoma are registered in the U.S. every year. Moreover, high cost of therapy, technologically advanced Therapy Types, developed health care amenities, and superior compensation plans are the key factors contributing to the growth of Pediatric Neuroblastoma Treatment market. The market in Asia Pacific is projected to increase at a high CAGR throughout the forecast period, because of improving health care amenity, rise in research and technological advancements in countries such as China and India. Key players operating in the Pediatric Neuroblastoma Treatment market are United Therapeutics Corporation, APEIRON Biologics AG, Baxter, Cellectar Biosciences, Inc., Pfizer, Inc., MacroGenics, Inc., and Bayer AG. The companies functioning in the market are concentrating on R&D investments and fund rising activities to drive clinical trials that lead to robust Therapy Type pipeline. As detection rate and market perception withstand to expand, there are anticipations for market growth during forecast period. Furthermore, innovative Therapy Type sanctions in the market will further drive the market growth. The objective of the report is to present a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, industry-validated market data and projections with a suitable set of assumptions and methodology. The report also helps in understanding Pediatric Neuroblastoma Treatment market dynamics, structure by identifying and analyzing the market segments and project the global market size. Further, the report also focuses on the competitive analysis of key players by Therapy Type, price, financial position, Therapy Type portfolio, growth strategies, and regional presence. The report also provides PEST analysis, PORTER’s analysis, and SWOT analysis to address the question of shareholders to prioritizing the efforts and investment shortly to the emerging segment in the market.
Scope of the Pediatric Neuroblastoma Treatment Market: Inquire before buying
Global Pediatric Neuroblastoma Treatment Market Report Coverage Details Base Year: 2022 Forecast Period: 2023-2029 Historical Data: 2018 to 2022 Market Size in 2022: US $ 1.96 Bn. Forecast Period 2023 to 2029 CAGR: 10.2% Market Size in 2029: US $ 3.88 Bn. Segments Covered: by Therapy Type Hospital Pharmacies Retail Pharmacies & Drug Stores Others by Type Immunotherapy Chemotherapy Others Pediatric Neuroblastoma Treatment Market, By Region
North America (United States, Canada and Mexico) Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe) Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC) Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A) South America (Brazil, Argentina Rest of South America)Pediatric Neuroblastoma Treatment Market Key Players are:
1.United Therapeutics Corporation 2.APEIRON Biologics AG 3.Baxter 4.Cellectar Biosciences, Inc. 5.Pfizer, Inc. 6.MacroGenics, Inc. 7.Bayer AG. 8.Sun Pharmaceutical Industries, Inc. 9.Sartorius AG. 10.APAC Biotech 11.EUSA Pharma 12.Y-mAbs Therapeutics, Inc. 13.Bristol Myers Company 14.Teva Pharmaceutical Industries Ltd.Frequently Asked questions
1. What is the market size of the Global Pediatric Neuroblastoma Treatment Market in 2022? Ans. The market size Global market in 2022 was US$ 1.96 Billion. 2. What are the different segments of the Global Pediatric Neuroblastoma Treatment Market? Ans. The Global market is divided into Product, Application and Distribution Channel. 3. What is the study period of this market? Ans. The Global Pediatric Neuroblastoma Treatment Market will be studied from 2022 to 2029. 4. Which region is expected to hold the highest Global Pediatric Neuroblastoma Treatment Market share? Ans. The Asia Pacific dominates the market share in the market. 5. What is the Forecast Period of Global Pediatric Neuroblastoma Treatment Market? Ans. The Forecast Period of the market is 2023-2029 in the market.
Global Pediatric Neuroblastoma Treatment Market
1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Pediatric Neuroblastoma Treatment Market Size, by Market Value (US$ Mn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Global Pediatric Neuroblastoma Treatment Market Analysis and Forecast 6.1. Global Pediatric Neuroblastoma Treatment Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global Pediatric Neuroblastoma Treatment Market Analysis and Forecast, By Therapy Type 7.1. Introduction and Definition 7.2. Key Findings 7.3. Global Pediatric Neuroblastoma Treatment Market Value Share Analysis, By Therapy Type 7.4. Global Pediatric Neuroblastoma Treatment Market Size (US$ Mn) Forecast, By Therapy Type 7.5. Global Pediatric Neuroblastoma Treatment Market Analysis, By Therapy Type 7.6. Global Pediatric Neuroblastoma Treatment Market Attractiveness Analysis, By Therapy Type 8. Global Pediatric Neuroblastoma Treatment Market Analysis and Forecast, By Distribution Channel 8.1. Introduction and Definition 8.2. Key Findings 8.3. Global Pediatric Neuroblastoma Treatment Market Value Share Analysis, By Distribution Channel 8.4. Global Pediatric Neuroblastoma Treatment Market Size (US$ Mn) Forecast, By Distribution Channel 8.5. Global Pediatric Neuroblastoma Treatment Market Analysis, By Distribution Channel 8.6. Global Pediatric Neuroblastoma Treatment Market Attractiveness Analysis, By Distribution Channel 9. Global Pediatric Neuroblastoma Treatment Market Analysis, by Region 9.1. Global Pediatric Neuroblastoma Treatment Market Value Share Analysis, by Region 9.2. Global Pediatric Neuroblastoma Treatment Market Size (US$ Mn) Forecast, by Region 9.3. Global Pediatric Neuroblastoma Treatment Market Attractiveness Analysis, by Region 10. North America Pediatric Neuroblastoma Treatment Market Analysis 10.1. Key Findings 10.2. North America Pediatric Neuroblastoma Treatment Market Overview 10.3. North America Pediatric Neuroblastoma Treatment Market Value Share Analysis, By Therapy Type 10.4. North America Pediatric Neuroblastoma Treatment Market Forecast, By Therapy Type 10.4.1. Immunotherapy 10.4.2. Chemotherapy 10.4.3. Others 10.5. North America Pediatric Neuroblastoma Treatment Market Value Share Analysis, By Distribution Channel 10.6. North America Pediatric Neuroblastoma Treatment Market Forecast, By Distribution Channel 10.6.1. Hospital Pharmacies 10.6.2. Retail Pharmacies & Drug Stores 10.6.3. Others 10.7. North America Pediatric Neuroblastoma Treatment Market Value Share Analysis, by Country 10.8. North America Pediatric Neuroblastoma Treatment Market Forecast, by Country 10.8.1. U.S. 10.8.2. Canada 10.9. North America Pediatric Neuroblastoma Treatment Market Analysis, by Country 10.10. U.S. Pediatric Neuroblastoma Treatment Market Forecast, By Therapy Type 10.10.1. Immunotherapy 10.10.2. Chemotherapy 10.10.3. Others 10.11. U.S. Pediatric Neuroblastoma Treatment Market Forecast, By Distribution Channel 10.11.1. Hospital Pharmacies 10.11.2. Retail Pharmacies & Drug Stores 10.11.3. Others 10.12. Canada Pediatric Neuroblastoma Treatment Market Forecast, By Therapy Type 10.12.1. Immunotherapy 10.12.2. Chemotherapy 10.12.3. Others 10.13. Canada Pediatric Neuroblastoma Treatment Market Forecast, By Distribution Channel 10.13.1. Hospital Pharmacies 10.13.2. Retail Pharmacies & Drug Stores 10.13.3. Others 10.14. North America Pediatric Neuroblastoma Treatment Market Attractiveness Analysis 10.14.1. By Therapy Type 10.14.2. By Distribution Channel 10.15. PEST Analysis 10.16. Key Trends 10.17. Key Developments 11. Europe Pediatric Neuroblastoma Treatment Market Analysis 11.1. Key Findings 11.2. Europe Pediatric Neuroblastoma Treatment Market Overview 11.3. Europe Pediatric Neuroblastoma Treatment Market Value Share Analysis, By Therapy Type 11.4. Europe Pediatric Neuroblastoma Treatment Market Forecast, By Therapy Type 11.4.1. Immunotherapy 11.4.2. Chemotherapy 11.4.3. Others 11.5. Europe Pediatric Neuroblastoma Treatment Market Value Share Analysis, By Distribution Channel 11.6. Europe Pediatric Neuroblastoma Treatment Market Forecast, By Distribution Channel 11.6.1. Hospital Pharmacies 11.6.2. Retail Pharmacies & Drug Stores 11.6.3. Others 11.7. Europe Pediatric Neuroblastoma Treatment Market Value Share Analysis, by Country 11.8. Europe Pediatric Neuroblastoma Treatment Market Forecast, by Country 11.8.1. Germany 11.8.2. U.K. 11.8.3. France 11.8.4. Italy 11.8.5. Spain 11.8.6. Rest of Europe 11.9. Europe Pediatric Neuroblastoma Treatment Market Analysis, by Country 11.10. Germany Pediatric Neuroblastoma Treatment Market Forecast, By Therapy Type 11.10.1. Immunotherapy 11.10.2. Chemotherapy 11.10.3. Others 11.11. Germany Pediatric Neuroblastoma Treatment Market Forecast, By Distribution Channel 11.11.1. Hospital Pharmacies 11.11.2. Retail Pharmacies & Drug Stores 11.11.3. Others 11.12. U.K. Pediatric Neuroblastoma Treatment Market Forecast, By Therapy Type 11.12.1. Immunotherapy 11.12.2. Chemotherapy 11.12.3. Others 11.13. U.K. Pediatric Neuroblastoma Treatment Market Forecast, By Distribution Channel 11.13.1. Hospital Pharmacies 11.13.2. Retail Pharmacies & Drug Stores 11.13.3. Others 11.14. France Pediatric Neuroblastoma Treatment Market Forecast, By Therapy Type 11.14.1. Immunotherapy 11.14.2. Chemotherapy 11.14.3. Others 11.15. France Pediatric Neuroblastoma Treatment Market Forecast, By Distribution Channel 11.15.1. Hospital Pharmacies 11.15.2. Retail Pharmacies & Drug Stores 11.15.3. Others 11.16. Italy Pediatric Neuroblastoma Treatment Market Forecast, By Therapy Type 11.16.1. Immunotherapy 11.16.2. Chemotherapy 11.16.3. Others 11.17. Italy Pediatric Neuroblastoma Treatment Market Forecast, By Distribution Channel 11.17.1. Hospital Pharmacies 11.17.2. Retail Pharmacies & Drug Stores 11.17.3. Others 11.18. Spain Pediatric Neuroblastoma Treatment Market Forecast, By Therapy Type 11.18.1. Immunotherapy 11.18.2. Chemotherapy 11.18.3. Others 11.19. Spain Pediatric Neuroblastoma Treatment Market Forecast, By Distribution Channel 11.19.1. Hospital Pharmacies 11.19.2. Retail Pharmacies & Drug Stores 11.19.3. Others 11.20. Rest of Europe Pediatric Neuroblastoma Treatment Market Forecast, By Therapy Type 11.20.1. Immunotherapy 11.20.2. Chemotherapy 11.20.3. Others 11.21. Rest of Europe Pediatric Neuroblastoma Treatment Market Forecast, By Distribution Channel 11.21.1. Hospital Pharmacies 11.21.2. Retail Pharmacies & Drug Stores 11.21.3. Others 11.22. Europe Pediatric Neuroblastoma Treatment Market Attractiveness Analysis 11.22.1. By Therapy Type 11.22.2. By Distribution Channel 11.23. PEST Analysis 11.24. Key Trends 11.25. Key Developments 12. Asia Pacific Pediatric Neuroblastoma Treatment Market Analysis 12.1. Key Findings 12.2. Asia Pacific Pediatric Neuroblastoma Treatment Market Overview 12.3. Asia Pacific Pediatric Neuroblastoma Treatment Market Value Share Analysis, By Therapy Type 12.4. Asia Pacific Pediatric Neuroblastoma Treatment Market Forecast, By Therapy Type 12.4.1. Immunotherapy 12.4.2. Chemotherapy 12.4.3. Others 12.5. Asia Pacific Pediatric Neuroblastoma Treatment Market Value Share Analysis, By Distribution Channel 12.6. Asia Pacific Pediatric Neuroblastoma Treatment Market Forecast, By Distribution Channel 12.6.1. Hospital Pharmacies 12.6.2. Retail Pharmacies & Drug Stores 12.6.3. Others 12.7. Asia Pacific Pediatric Neuroblastoma Treatment Market Value Share Analysis, by Country 12.8. Asia Pacific Pediatric Neuroblastoma Treatment Market Forecast, by Country 12.8.1. China 12.8.2. India 12.8.3. Japan 12.8.4. ASEAN 12.8.5. Rest of Asia Pacific 12.9. Asia Pacific Pediatric Neuroblastoma Treatment Market Analysis, by Country 12.10. China Pediatric Neuroblastoma Treatment Market Forecast, By Therapy Type 12.10.1. Immunotherapy 12.10.2. Chemotherapy 12.10.3. Others 12.11. China Pediatric Neuroblastoma Treatment Market Forecast, By Distribution Channel 12.11.1. Hospital Pharmacies 12.11.2. Retail Pharmacies & Drug Stores 12.11.3. Others 12.12. India Pediatric Neuroblastoma Treatment Market Forecast, By Therapy Type 12.12.1. Immunotherapy 12.12.2. Chemotherapy 12.12.3. Others 12.13. India Pediatric Neuroblastoma Treatment Market Forecast, By Distribution Channel 12.13.1. Hospital Pharmacies 12.13.2. Retail Pharmacies & Drug Stores 12.13.3. Others 12.14. Japan Pediatric Neuroblastoma Treatment Market Forecast, By Therapy Type 12.14.1. Immunotherapy 12.14.2. Chemotherapy 12.14.3. Others 12.15. Japan Pediatric Neuroblastoma Treatment Market Forecast, By Distribution Channel 12.15.1. Hospital Pharmacies 12.15.2. Retail Pharmacies & Drug Stores 12.15.3. Others 12.16. ASEAN Pediatric Neuroblastoma Treatment Market Forecast, By Therapy Type 12.16.1. Immunotherapy 12.16.2. Chemotherapy 12.16.3. Others 12.17. ASEAN Pediatric Neuroblastoma Treatment Market Forecast, By Distribution Channel 12.17.1. Hospital Pharmacies 12.17.2. Retail Pharmacies & Drug Stores 12.17.3. Others 12.18. Rest of Asia Pacific Pediatric Neuroblastoma Treatment Market Forecast, By Therapy Type 12.18.1. Immunotherapy 12.18.2. Chemotherapy 12.18.3. Others 12.19. Rest of Asia Pacific Pediatric Neuroblastoma Treatment Market Forecast, By Distribution Channel 12.19.1. Hospital Pharmacies 12.19.2. Retail Pharmacies & Drug Stores 12.19.3. Others 12.20. Asia Pacific Pediatric Neuroblastoma Treatment Market Attractiveness Analysis 12.20.1. By Therapy Type 12.20.2. By Distribution Channel 12.21. PEST Analysis 12.22. Key Trends 12.23. Key Developments 13. Middle East & Africa Pediatric Neuroblastoma Treatment Market Analysis 13.1. Key Findings 13.2. Middle East & Africa Pediatric Neuroblastoma Treatment Market Overview 13.3. Middle East & Africa Pediatric Neuroblastoma Treatment Market Value Share Analysis, By Therapy Type 13.4. Middle East & Africa Pediatric Neuroblastoma Treatment Market Forecast, By Therapy Type 13.4.1. Immunotherapy 13.4.2. Chemotherapy 13.4.3. Others 13.5. Middle East & Africa Pediatric Neuroblastoma Treatment Market Value Share Analysis, By Distribution Channel 13.6. Middle East & Africa Pediatric Neuroblastoma Treatment Market Forecast, By Distribution Channel 13.6.1. Hospital Pharmacies 13.6.2. Retail Pharmacies & Drug Stores 13.6.3. Others 13.7. Middle East & Africa Pediatric Neuroblastoma Treatment Market Value Share Analysis, by Country 13.8. Middle East & Africa Pediatric Neuroblastoma Treatment Market Forecast, by Country 13.8.1. GCC 13.8.2. South Africa 13.8.3. Rest of Middle East & Africa 13.9. Middle East & Africa Pediatric Neuroblastoma Treatment Market Analysis, by Country 13.10. GCC Pediatric Neuroblastoma Treatment Market Forecast, By Therapy Type 13.10.1. Immunotherapy 13.10.2. Chemotherapy 13.10.3. Others 13.11. GCC Pediatric Neuroblastoma Treatment Market Forecast, By Distribution Channel 13.11.1. Hospital Pharmacies 13.11.2. Retail Pharmacies & Drug Stores 13.11.3. Others 13.12. South Africa Pediatric Neuroblastoma Treatment Market Forecast, By Distribution Channel 13.12.1. Hospital Pharmacies 13.12.2. Retail Pharmacies & Drug Stores 13.12.3. Others 13.13. Rest of Middle East & Africa Pediatric Neuroblastoma Treatment Market Forecast, By Therapy Type 13.13.1. Immunotherapy 13.13.2. Chemotherapy 13.13.3. Others 13.14. Rest of Middle East & Africa Pediatric Neuroblastoma Treatment Market Forecast, By Distribution Channel 13.14.1. Hospital Pharmacies 13.14.2. Retail Pharmacies & Drug Stores 13.14.3. Others 13.15. Middle East & Africa Pediatric Neuroblastoma Treatment Market Attractiveness Analysis 13.15.1. By Therapy Type 13.15.2. By Distribution Channel 13.16. PEST Analysis 13.17. Key Trends 13.18. Key Developments 14. South America Pediatric Neuroblastoma Treatment Market Analysis 14.1. Key Findings 14.2. South America Pediatric Neuroblastoma Treatment Market Overview 14.3. South America Pediatric Neuroblastoma Treatment Market Value Share Analysis, By Therapy Type 14.4. South America Pediatric Neuroblastoma Treatment Market Forecast, By Therapy Type 14.4.1. Immunotherapy 14.4.2. Chemotherapy 14.4.3. Others 14.5. South America Pediatric Neuroblastoma Treatment Market Value Share Analysis, By Distribution Channel 14.6. South America Pediatric Neuroblastoma Treatment Market Forecast, By Distribution Channel 14.6.1. Hospital Pharmacies 14.6.2. Retail Pharmacies & Drug Stores 14.6.3. Others 14.7. South America Pediatric Neuroblastoma Treatment Market Value Share Analysis, by Country 14.8. South America Pediatric Neuroblastoma Treatment Market Forecast, by Country 14.8.1. Brazil 14.8.2. Mexico 14.8.3. Rest of South America 14.9. South America Pediatric Neuroblastoma Treatment Market Analysis, by Country 14.10. Brazil Pediatric Neuroblastoma Treatment Market Forecast, By Therapy Type 14.10.1. Immunotherapy 14.10.2. Chemotherapy 14.10.3. Others 14.11. Brazil Pediatric Neuroblastoma Treatment Market Forecast, By Distribution Channel 14.11.1. Hospital Pharmacies 14.11.2. Retail Pharmacies & Drug Stores 14.11.3. Others 14.12. Mexico Pediatric Neuroblastoma Treatment Market Forecast, By Therapy Type 14.12.1. Immunotherapy 14.12.2. Chemotherapy 14.12.3. Others 14.13. Mexico Pediatric Neuroblastoma Treatment Market Forecast, By Distribution Channel 14.13.1. Hospital Pharmacies 14.13.2. Retail Pharmacies & Drug Stores 14.13.3. Others 14.14. Rest of South America Pediatric Neuroblastoma Treatment Market Forecast, By Therapy Type 14.14.1. Immunotherapy 14.14.2. Chemotherapy 14.14.3. Others 14.15. Rest of South America Pediatric Neuroblastoma Treatment Market Forecast, By Distribution Channel 14.15.1. Hospital Pharmacies 14.15.2. Retail Pharmacies & Drug Stores 14.15.3. Others 14.16. South America Pediatric Neuroblastoma Treatment Market Attractiveness Analysis 14.16.1. By Therapy Type 14.16.2. By Distribution Channel 14.17. PEST Analysis 14.18. Key Trends 14.19. Key Developments 15. Company Profiles 15.1. Market Share Analysis, by Company 15.2. Competition Matrix 15.2.1. Competitive Benchmarking of key players by price, presence, market share, Distribution Channels and R&D investment 15.2.2. New Treatment Center Launches and Treatment Center Enhancements 15.2.3. Market Consolidation 15.2.3.1. M&A by Regions, Investment and Distribution Channels 15.2.3.2. M&A Key Players, Forward Integration and Backward Integration 15.3. Company Profiles: Key Players 15.3.1. United Therapeutics Corporation 15.3.1.1. Company Overview 15.3.1.2. Financial Overview 15.3.1.3. Treatment Center Portfolio 15.3.1.4. Business Strategy 15.3.1.5. Recent Developments 15.3.1.6. Company Footprint 15.3.2. APEIRON Biologics AG 15.3.3. Baxter 15.3.4. Cellectar Biosciences, Inc. 15.3.5. Pfizer, Inc. 15.3.6. MacroGenics, Inc. 15.3.7. Bayer AG. 15.3.8. Sun Pharmaceutical Industries, Inc. 15.3.9. Sartorius AG. 15.3.10. APAC Biotech 15.3.11. EUSA Pharma 15.3.12. Y-mAbs Therapeutics, Inc. 15.3.13. Bristol Myers Company 15.3.14. Teva Pharmaceutical Industries Ltd. 16. Primary Key Insights